Chemomab Therapeutics Ltd. announced that Jill M. Quigley, JD, has been appointed to the Chemomab board of directors. Ms. Quigley brings more than 20 years of biotechnology industry leadership experience encompassing executive management, corporate operations, legal affairs, financings, and board membership. She brings an exceptionally well-rounded suite of biotechnology skills and experience to Chemomab.

Building on her initial expertise in legal affairs, Jill broadened her capabilities and experience, ultimately serving as head of operations and chief executive of biotechnology firms developing important innovative products for rare diseases. She has worked extensively with public companies, established domestic and international operations, helped lead major financing rounds and served as a senior executive at a U.S.-Israeli biopharmaceutical firm. Until December 2021, Ms. Quigley was Chief Operating Officer at Passage Bio, a publicly traded gene therapy company.

Previously, she served as Chief Executive Officer and General Counsel of Nutrinia, a developer of novel treatments for rare gastrointestinal diseases. Earlier, Ms. Quigley served as Senior Counsel at NPS Pharmaceuticals, a publicly traded biotechnology company that was acquired by Shire; as Corporate Counsel for Pharmasset, a publicly traded biotechnology firm that was acquired by Gilead Sciences; and as Assistant Corporate Counsel for publicly traded Integra Life Sciences. Earlier in her career she was an Associate with the law firm of Dechert LLP.

Ms. Quigley holds a BA degree from American University and a JD from Rutgers School of Law.Ms. Quigley, who is filling an open position on the Chemomab board, will serve on Chemomab's Audit Committee. She currently is also a member of the board of directors of publicly traded Terns Pharmaceuticals, where she is Chair of the Audit Committee.